Multiple TKIs (sorafenib, regorafenib, cabozantinib, and lenvatinib), ICIs (nivolumab and pembrolizumab), and vascular endothelial growth factor inhibitors (bevacizumab) have been used to systemically treat advanced HCC. The gene discussed is VEGFA; the disease is hepatocellular carcinoma.